Nitropaste in Breast Reduction
PT
Overseen byPeter Taub, M.D.
Age: 18 - 65
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Icahn School of Medicine at Mount Sinai
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial is testing whether applying Nitroglycerin paste can help wounds heal better and reduce scarring after breast reduction surgery. The paste works by increasing blood flow to the treated area. Patients will be monitored over time to see how well their wounds heal.
Research Team
PT
Peter Taub, M.D.
Principal Investigator
Icahn School of Medicine at Mount Sinai
Eligibility Criteria
Inclusion Criteria
Patients who are female and transmen
Undergoing bilateral breast reduction via Mount Sinai Plastic Surgery Clinic
Reduction must be performed via Wise incisional pattern
Treatment Details
Interventions
- Nitroglycerin Paste (Vasodilator)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nitroglycerine pasteExperimental Treatment2 Interventions
The randomized breast will receive Nitroglycerine paste and Dermabond.
Group II: DermabondPlacebo Group1 Intervention
The control breast will receive Dermabond only
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
Trials
933
Recruited
579,000+
Dr. Brendan Carr
Icahn School of Medicine at Mount Sinai
Chief Executive Officer since 2024
MD, MA, MS
Dr. Vicki LoPachin
Icahn School of Medicine at Mount Sinai
Chief Medical Officer
MD, FACP, MBA